Adamax

Adamax is a lab-made analog of Semax, built on the same ACTH(4-7) fragment backbone (Met-Glu-His-Phe-Pro-Gly-Pro) but carrying two structural changes: acetylation at the N-terminus and an adamantane cage attached at the C-terminal end. That cage is the reason the molecule exists. Being highly lipophilic, it helps the peptide cross membranes more readily, resists enzymatic breakdown, and is intended to reach the brain more efficiently and stay active longer than standard Semax or N-Acetyl Semax.

The compound is a direct descendant of Semax, the Russian-developed nootropic and neuroprotective peptide, and applies the same adamantane strategy used in analogs such as P21. The goal behind the design is straightforward: keep the BDNF-driven neuroprotective character of Semax, but stretch its duration and get more of each dose where it needs to go. Worth noting up front is that no standardized dosing exists for this analog. Figures circulating through vendors and research forums vary by more than tenfold, so treat any quantity below as informal convention, not a validated protocol.

• BDNF mimicry with TrkB sensitization is the leading proposed pathway, strengthening brain-derived neurotrophic factor signaling in ways associated with long-term potentiation, neuronal survival, and the consolidation of memory.

• Better brain access via adamantane, where the lipophilic cage improves membrane permeability and blunts enzymatic degradation, so a greater share of each dose arrives intact relative to unmodified Semax.

• Acetylation at the N-terminus adds proteolytic resistance, shielding the amino end from enzyme activity and working together with the adamantane group to lengthen the functional half-life.

• Secondary MC4 receptor activity has been reported, with knock-on modulation of dopamine, acetylcholine, glutamate, and GABA signaling that may account for the wider cognitive and mood-related effects.

• A different mechanism than HGF/c-Met compounds like Dihexa, which drives synaptogenesis through hepatocyte growth factor and c-Met potentiation. The two occupy complementary neurotrophic territory rather than duplicating each other.

• Longer-lasting than Semax, which is the central argument for the adamantane modification: one dose may cover a wider functional window than standard Semax or N-Acetyl Semax.

• More of each dose reaches the brain, which in theory means smaller amounts can match Semax-level central effects, though controlled human research has not confirmed this directly.

• Support for memory and cognition, drawing on the same BDNF and TrkB mechanism as its Semax parent, where work on that pathway points to benefits for operative memory and attention.

• Workable without injections, since the adamantane group is what allows intranasal and sublingual routes to achieve meaningful uptake while still acting on central nervous system pathways.

• Neuroprotective promise in line with the wider Semax family, where upregulation of BDNF and TrkB has been linked to neuronal survival and resilience in related research.

Note: Late-day dosing is best avoided, since the lift in alertness and energy can cut into sleep for some users. Headaches, when they show up, usually clear once a choline source is added.

These three peptides are frequently lumped together, yet they are not substitutes for one another. Adamax carries the reputation of being the most potent of the group, and that reputation traces back to the adamantane modification that lengthens its action and helps it cross into the brain more effectively than plain Semax. Semax covers similar ground without that enhancement, which also makes it the better-documented and more established of the pair.

Selank has a different structure altogether but keeps company with the other two in discussion because of its calming, anxiolytic character, a contrast to the sharper, more stimulating focus associated with Adamax and Semax. Deciding which one suits a particular research goal generally comes down to assessing each on its own, as reported responses differ considerably from person to person.

• Side effects appear limited in theory, and the compound is usually described as clean, but with no formal human clinical safety dataset behind it that description is a starting assumption rather than an assurance.

• Mild sluggishness or an over-calming effect has been reported by some users, varying with individual sensitivity and the amount used.

• Anxiety has been reported by others, despite the compound's largely calming reputation, which shows how widely individual responses can diverge.

• No human clinical safety data exists, and this is the caveat that matters most here. Everything known comes from Semax parent-compound literature, vendor material, and informal community reports.

• It remains a novel compound, so first-hand observation currently carries more practical weight than the thin published record, making careful characterization and self-monitoring especially important.

Cognitive Stack

• Adamax

• Selank

• NAD+

Disclaimer: The information provided is intended solely for educational purposes and should not be considered a replacement for professional medical advice. All compounds referenced are not for human consumption.